Navigation Links
Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

cipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:4/17/2015)... , April 17, 2015 Today, ... honored 13 employees from 12 biopharmaceutical companies as ... efforts in policy advocacy and community service. ... Health Champion Awards were created by the biopharmaceutical ... excelled in their careers, but have also shown ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals ... focused on the development and commercialization of products for ... it will release results for the first quarter of ... closes. The Company will host a ... 6, 2015, during which Vanda management will discuss the ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... update webcast/conference call after the market closes on January ... Vicente Anido, Jr., Ph.D., and Chief Financial Officer and ... 2011 guidance, give a commercial and new product pipeline ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2
(Date:4/18/2015)... 18, 2015 "I wanted to ... create a healthful juice that contained essential vitamins, ... Md. "It increases my energy, improves skin elasticity ... He developed Tapp's Juice to contain fruits, vegetables ... prevent physical and mental fatigue. It features a ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... 2015 Rosetta Radiology is proud to ... their list of diagnostic imaging services. This solidifies them ... the Upper East Side of Manhattan. , The new ... The addition of PET-CT, combined with Rosetta’s state of ... to work with patients through several stages of the ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2
... American Society,for Therapeutic Radiology and Oncology is pleased to ... Oriental Republic of,Uruguay, will present a special guest lecture ... 1 in Los Angeles. Dr. Vazquez, who,is a radiation ... speak October 30 at 9:00 a.m. at the Los ...
... but not all , WEDNESDAY, Oct. 17 (HealthDay News) -- ... pain. , That,s the conclusion of Israeli researchers who reviewed ... insoles to sham insoles or no treatment for back pain ... of 256 people that focused on the use of insoles ...
... Help Advance Research-, MISSION VIEJO, Calif., Oct. ... for its innovative genomic search,technology, SLIM Search(TM), Inc. ... The SLIM Search genomic search tool delivers greater ... 1.3 includes the following features: * ...
... 17 After completing its review of safety,and ... Board (DSMB) has recommended that the pivotal Phase ... Edema) Study,continue under the current protocol, without change. ... for the treatment of diabetic macular edema (DME). ...
... Oct. 17 IRIDEX,Corporation (Nasdaq: IRIX ) announced ... and Chief Executive Officer, and as a member of,the ... The Board of,Directors has appointed Theodore A. Boutacoff, who ... Directors, to serve as the Company,s President,and Chief Executive ...
... - For the Nine Months (to 31 August) a 46% Sales ... in EBIT to EUR34.8m (EUR6.2m) - Marked Improvement in Adjusted ... Fall in Interest Charges Since the IPO - CEO Dr. ... In the first nine months of its financial year (to ...
Cached Medicine News:Health News:President of Uruguay to Speak at ASTRO Annual Meeting 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 3Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 5
... cool-running, energy efficient LEDs (Light Emitting Diodes) ... see without affecting the darkened refracting environment. ... free so you'll never need to change ... a limited lifetime warranty, the best in ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: